Top ▲
target has curated data in GtoImmuPdb
Target id: 1629
Nomenclature: MMP2
Family: M10: Matrix metallopeptidase
This target is also described as a ligand entry: matrix metalloproteinase 2; matrix metalloproteinase 2; matrix metalloproteinase 2
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 660 | 16q12.2 | MMP2 | matrix metallopeptidase 2 | |
Mouse | - | 662 | 8 44.99 cM | Mmp2 | matrix metallopeptidase 2 | |
Rat | - | 662 | 19p11 | Mmp2 | matrix metallopeptidase 2 |
Previous and Unofficial Names |
TBE- 1 | gelatinase A | CLG4 | CLG4A | matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase) |
Database Links | |
Specialist databases | |
MEROPS | M10.003 (Hs) |
Other databases | |
Alphafold | P08253 (Hs), P33434 (Mm), P33436 (Rn) |
BRENDA | 3.4.24.24 |
CATH/Gene3D | 2.10.10.10, 2.110.10.10, 3.40.390.10, 1.10.101.10 |
ChEMBL Target | CHEMBL333 (Hs), CHEMBL3095 (Mm), CHEMBL1075175 (Rn) |
DrugBank Target | P08253 (Hs) |
Ensembl Gene | ENSG00000087245 (Hs), ENSMUSG00000031740 (Mm), ENSRNOG00000016695 (Rn) |
Entrez Gene | 4313 (Hs), 17390 (Mm), 81686 (Rn) |
Human Protein Atlas | ENSG00000087245 (Hs) |
KEGG Enzyme | 3.4.24.24 |
KEGG Gene | hsa:4313 (Hs), mmu:17390 (Mm), rno:81686 (Rn) |
OMIM | 120360 (Hs) |
Orphanet | ORPHA123439 (Hs) |
Pharos | P08253 (Hs) |
RefSeq Nucleotide | NM_004530 (Hs), NM_001127891 (Hs), NM_008610 (Mm), NM_031054 (Rn) |
RefSeq Protein | NP_004521 (Hs), NP_001121363 (Hs), NP_032636 (Mm), NP_112316 (Rn) |
UniProtKB | P08253 (Hs), P33434 (Mm), P33436 (Rn) |
Wikipedia | MMP2 (Hs) |
Selected 3D Structures | |||||||||||||
|
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
MMP2 is included in GtoImmuPdb based on its potential involvement in asthma. |
Immuno Process Associations | ||
|
||
|
||
|
Immuno Disease Associations | ||||||||||
|
Clinically-Relevant Mutations and Pathophysiology | ||||||||||||
|
||||||||||||
|
General Comments |
Matrix metalloproteinase-2 (MMP2) is a zinc-dependent endopeptidase that degrades extracellular matrix proteins. It is being explored as a drug target in cancer, arthritis, and fibrosis. Selective inhibitors are in development. |
1. Brown S, Bernardo MM, Li Z-H, Kotra LP, Tanaka Y, Fridman R, Mobashery S. (2000) Potent and Selective Mechanism-Based Inhibition of Gelatinases. J Am Chem Soc, 122: 6799-6800.
2. Cataldo D, Munaut C, Noël A, Frankenne F, Bartsch P, Foidart JM, Louis R. (2000) MMP-2- and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int Arch Allergy Immunol, 123 (3): 259-67. [PMID:11112863]
3. Fisher JF, Mobashery S. (2006) Recent advances in MMP inhibitor design. Cancer Metastasis Rev, 25 (1): 115-36. [PMID:16680577]
4. Ma D, Wu W, Yang G, Li J, Li J, Ye Q. (2004) Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. Bioorg Med Chem Lett, 14 (1): 47-50. [PMID:14684295]
5. MRC. AZD6605 Matrix metallopeptidase 13 (MMP13) inhibitor. Accessed on 28/10/2014. Modified on 28/10/2014. MRC/AstraZeneca: Mechanisms of Disease Call, http://webarchive.nationalarchives.gov.uk/20120104105854/http://www.mrc.ac.uk/consumption/groups/public/documents/content/mrc008371.pdf
6. Nguyen TT, Ding D, Wolter WR, Pérez RL, Champion MM, Mahasenan KV, Hesek D, Lee M, Schroeder VA, Jones JI et al.. (2018) Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing. J Med Chem, 61 (19): 8825-8837. [PMID:30212201]
7. Nuti E, Casalini F, Santamaria S, Gabelloni P, Bendinelli S, Da Pozzo E, Costa B, Marinelli L, La Pietra V, Novellino E et al.. (2011) Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors. Eur J Med Chem, 46 (7): 2617-29. [PMID:21514700]
8. Rasmussen HS, McCann PP. (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther, 75 (1): 69-75. [PMID:9364582]
9. Takeuchi T, Hayashi M, Tamita T, Nomura Y, Kojima N, Mitani A, Takeda T, Hitaka K, Kato Y, Kamitani M et al.. (2022) Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem, 65 (12): 8493-8510. [PMID:35687819]
10. Tauro M, Laghezza A, Loiodice F, Agamennone M, Campestre C, Tortorella P. (2013) Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Bioorg Med Chem, 21 (21): 6456-65. [PMID:24071448]
11. Tuccinardi T, Martinelli A, Nuti E, Carelli P, Balzano F, Uccello-Barretta G, Murphy G, Rossello A. (2006) Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Bioorg Med Chem, 14 (12): 4260-76. [PMID:16483784]
M10: Matrix metallopeptidase: MMP2. Last modified on 12/07/2022. Accessed on 07/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1629.